SecBot SecBot
8-K ·Filed Nov 10, 2026

XCUR

EXICURE, INC.
NEUTRAL
Impact 5/10
Horizonweeks Processed6d 7h ago SEC0001193125-26-455339
8-K material event: Items 1.01
Actionable Insight • Neutral

Monitor the November 16, 2026 interim payment deadline and the receipt of the GPCR waiver and release, which are key closing conditions. If the deal closes, Exicure will have ~$4.8M in cash but no operating assets, increasing the likelihood of a reverse merger or liquidation. Failure to close could leave Exicure with ongoing liabilities and no clear path forward.

DirectionNeutral
Confidencehigh
Horizonweeks

GPC-100

◆ Mixed Named in this 8-K
Impact
Phase
Phase 2
Time to market
No timeline is estimable. The drug is still at Phase 2 with no announced Phase 3 plan under Exicure. The program is being sold to GPCRT Inc., making any go-to-market timeline dependent on the buyer's development strategy.
Next catalyst
None dated

What to watchWatch the November 16, 2026 interim payment deadline (KRW 2.0 billion) as a sign of deal commitment from GPCRT Inc., and the November 30, 2026 expected closing. If the deal closes, Exicure will have ~$4.8M cash but no operating assets. If it fails, Exicure faces a severe liquidity crunch with no pipeline and an active Nasdaq delisting notice.

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+1
Entry
$1.08
T+0 close · Nov 10, 2026 · via day close
Latest settled
+2.78%
T+1 · $1.11
Vs SPY
+1.46%
α at T+1
Next horizon
T+5
in 8h
  1. T+0 · Nov 10 $1.08entry
  2. T+1 · 6d ago +2.78%α +1.46% · $1.11
  3. T+4 · todayOpen
  4. T+5 · in 8h Pending
  5. T+20 · in 22d Pending
  6. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Exicure agreed to sell its GPC-100 (burixafor) program assets to GPCRT Inc. for KRW 6.5 billion (approximately US$4.8 million) in cash. The deal includes the license agreement, contracts, IP, clinical data and equipment, while Exicure retains its subsidiary GPCR USA and all pre-September 1, 2026 liabilities. The transaction is subject to closing conditions including a GPCR waiver and potential stockholder approval, and is part of Exicure's strategic alternatives review.

Key Financial Metrics

Deal Value
$4.8M
Deal Type
acquisition

Key Facts

  • Aggregate purchase price of KRW 6.5 billion (approximately US$4.8 million), payable entirely in cash
  • KRW 500 million deposit already paid; KRW 2.0 billion due on or before November 16, 2026; KRW 4.0 billion due at closing
  • Closing date is November 30, 2026, subject to satisfaction of conditions including GPCR waiver and release, regulatory approvals, third-party consents, and any required stockholder approval
  • GPCR USA remains a wholly owned subsidiary of Exicure after closing; no equity interests are being transferred
  • Purchaser assumes future milestone and royalty obligations under the License Agreement, plus program costs from September 1, 2026 onward
  • Exicure retains all pre-September 1, 2026 GPC-100 program liabilities, including unpaid CRO fees of US$644,383.49 and sublease obligations of US$782,897.71
  • 90% of purchase price allocated to rights under the License Agreement; 10% to assigned contracts and other assets; 0% to IP and goodwill
  • Company market cap is $6M; the $4.8M deal value represents approximately 80% of market cap

Financial Impact

Cash inflow of KRW 6.5 billion (approx. US$4.8 million) to Exicure, representing ~80% of its $6M market cap. Exicure sheds future GPC-100 development costs but retains significant pre-close liabilities.

cashliabilitiesrevenue

Risk Factors

  • Closing conditions may not be satisfied, including GPCR waiver, third-party consents, and potential stockholder approval
  • Purchaser may fail to make the interim or final payments when due
  • Exicure retains significant pre-September 1, 2026 liabilities including $644K in unpaid CRO fees and $783K in sublease obligations
  • Following the sale, Exicure will have limited or no operating business, raising going concern and Nasdaq listing risks

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
0% bullish (6 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-455339
Document: xcur-20261104.htm0001193125-26-455339
Document: xcur-ex99_1.htm0001193125-26-455339
Document: 0001193125-26-455339-index-headers.html0001193125-26-455339
Document: 0001193125-26-455339-index.html0001193125-26-455339
Document: 0001193125-26-455339.txt0001193125-26-455339

Track record

9 reports on XCUR

Performance horizon

1 of 3 bullish or bearish reports moved the stock their way by T+1. Best: +40.56% at T+60 after the Mar 25, 2026 report. 2 of 3 went positive at some point.

Filters
  1. Nov 16, 2026today Press Release Bearish 5/10 Entry $1.07 Now $1.07 −0.00% settles Nov 18
  2. Nov 12, 20264d ago DEF 14A Bearish 6/10 Entry $1.06 to $1.08 Now $1.07 −0.94% ▼ −1.89% −2.25% vs SPY
  3. Nov 10, 20266d ago 8-K Neutral 5/10 Viewing Entry $1.08 to $1.11 Now $1.07 −0.93% ▲ +2.78% +1.46% vs SPY
  4. Sep 16, 20268w ago 8-K Bearish 7/10 Entry $1.33 to $1.35 Now $1.07 +19.55% ▼ −1.50% −0.37% vs SPY
  5. Jun 30, 202619w ago 8-K Neutral 2/10 Entry $2.08 to $1.98 Now $1.07 −48.56% ▼ −4.81% −4.67% vs SPY
  6. Jun 1, 202624w ago Press Release Neutral 4/10 Entry $3.11 to $3.16 Now $1.07 −65.59% ▲ +1.61% +2.30% vs SPY
  7. Jun 1, 202624w ago 8-K Neutral 3/10 Entry $3.33 to $3.11 Now $1.07 −67.87% ▼ −6.61% −6.75% vs SPY
  8. Apr 10, 202631w ago 8-K Neutral 3/10 Entry $3.85 to $3.79 Now $1.07 −72.19% ▼ −1.56% −2.77% vs SPY
  9. Mar 25, 202633w ago Press Release Bearish 8/10 Entry $4.61 to $4.42 Now $1.07 +76.79% ▲ +4.23% +2.55% vs SPY
Showing 9 of 9

US Market Status

Market Closed · Opens Wed (10h 2m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 10, 2026